**SEC Form 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. **Name and Address of Reporting Person**
   
   Machiels Alec
   
   C/O APELLIS PHARMACEUTICALS, INC.
   100 FIFTH AVENUE, 3RD FLOOR
   
   WALTHAM, MA 02451

2. **Issuer Name and Ticker or Trading Symbol**
   
   Apellis Pharmaceuticals, Inc. [APLS]

3. **Date of Earliest Transaction (Month/Day/Year)**
   
   08/15/2022

4. **Individual or Joint/Group Filing (Check Applicable Line)**
   
   X Form filed by One Reporting Person
   
   X Form filed by More than One Reporting Person

5. **Relationship of Reporting Person(s) to Issuer**
   
   X Director
   
   10% Owner
   
   Officer (give title below)
   
   Other (specify below)

6. **Amount of Securities Beneficially Owned Following Reported Transaction(s)**
   
   250,000

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

<table>
<thead>
<tr>
<th>1. Title of Security (Instr. 3)</th>
<th>2. Transaction Date (Month/Day/Year)</th>
<th>3. Transaction Code (Instr. 8)</th>
<th>4. Number of Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)</th>
<th>5. Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common Stock</td>
<td>08/15/2022</td>
<td>M (1)</td>
<td>1,250 A</td>
<td>$2.67</td>
</tr>
<tr>
<td>Common Stock</td>
<td>08/15/2022</td>
<td>M (1)</td>
<td>1,250 D</td>
<td>$67.21</td>
</tr>
</tbody>
</table>

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**

<table>
<thead>
<tr>
<th>1. Title of Derivative Security (Instr. 3)</th>
<th>2. Conversion or Exercise Price of Derivative Security</th>
<th>3. Transaction Date (Month/Day/Year)</th>
<th>4. Transaction Code (Instr. 8)</th>
<th>5. Number of Derivative Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)</th>
<th>6. Date Exercisable and Expiration Date (Month/Day/Year)</th>
<th>7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)</th>
<th>8. Price of Derivative Security (Instr. 5)</th>
<th>9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)</th>
<th>10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)</th>
<th>11. Nature of Indirect Beneficial Ownership (Instr. 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stock Option (Right to Buy)</td>
<td>$2.67</td>
<td>08/15/2022</td>
<td>M (1)</td>
<td>1,250</td>
<td>(3)</td>
<td>12/04/2023</td>
<td>Common Stock</td>
<td>1,250</td>
<td>D</td>
<td>118,529 (2)</td>
</tr>
</tbody>
</table>

**Explanation of Responses:**

1. This is a scheduled exercise and sale from 10B5-1 trading plan.
2. Owned by spouse.
3. This option was granted on December 5, 2013 and fully vested.

**Signature of Reporting Person**

/s/ David Watson, attorney-in-fact for Alec Machiels

08/16/2022

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(iv).


Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.